Clinical Trials
4 trialsNCT03786783 2026-06-02
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT07537400 2026-04-17
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Shaare Zedek Medical Center
Phase 2 Not yet recruiting
NCT07437963 2026-04-15
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT02455557 2026-03-30
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting